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Whole blood Fe isotopic signature
in a sub-Saharan African population†
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Yulia Anoshkina,c Karl Vandepoele, d Philippe B. Katchunga,a
Antoine S. Kishabongo,e Marijn M. Speeckaert,f Frank Vanhaecke c and
Joris R. Delanghe *b
The Fe isotopic composition of an individual’s whole blood has recently been shown to be an
interesting clinical indicator of Fe status. The present study aimed to evaluate the influence of several
endemic characteristics of a representative population of the South Kivu province, an Fe-rich volcanic
African region, on the whole blood Fe isotopic composition. Both diabetes mellitus and the ferroportin
Q248H mutation are very common in Africa and are strongly associated with impairments in Fe
metabolism. Fe isotopic analysis of whole blood samples was carried out using multi-collector
inductively coupled plasma-mass spectrometry (after chromatographic isolation of the target element).
Forty-two male subjects (between 48 and 59 years old) living in Bukavu (South Kivu) were enrolled in
this study. Among the selected population, wild-type subjects and subjects presenting the ferroportin
Q248H mutation (heterozygotes and homozygotes) were included. Within each group, diabetic and
non-diabetic patients were considered. The whole blood d56Fe value ranged from 3.09% to 2.41%.
The d56Fe value shows a significant negative correlation with the ferritin concentration. No correlation
could be established between the whole blood d56Fe value and the transferrin concentration, transferrin
saturation or serum Fe concentration. The ferroportin Q248H mutation did not seem to have aﬀected
the whole blood Fe isotopic signature. The whole blood d56Fe values were significantly higher in diabetic
subjects than in non-diabetic subjects and showed a significant negative correlation with body mass
index (BMI) values.
1. Introduction
Almost all living organisms rely on Fe for the proper functioning of
several fundamental biological processes, for instance acting as
part of proteins and enzymes essential for oxygen transport and
storage, synthesis of DNA and electron transport.1
In nature, Fe consists of 4 stable isotopes, which are diﬀerent
in their masses and abundances: 54Fe (5.8%), 56Fe (91.8%), 57Fe
(2.1%), and 58Fe (0.3%).2 Due to the diﬀerence in their nuclear
masses, the isotopes may take part in biochemical reactions with a
slightly diﬀerent eﬃciency, resulting in mass-dependent Fe iso-
tope fractionation eﬀects throughout the Femetabolic pathways.3,4
It has been previously reported that the Fe isotopic composition
in whole blood shows a clear correlation with the serum ferritin
concentration, and therefore stands out as a valuable tool to assess
body Fe status.5 Works in this direction have been predominantly
reported on Western European populations.6–11 However, Hotz
andWalczyk used the Fe isotopic composition of blood samples to
compare Fe absorption efficiencies in Swiss and Thai women.12
Ohno et al. used Fe isotopic analysis of red blood cells to
characterize the Fe isotopic signature of a Japanese population,13
and Jaouen et al. carried out a comparative study between a French
and a Russian (Yakut) population of different ages.14 Fe intestinal
absorption and Fe partitioning between blood and Fe-storage
organs seem to be the principal processes accompanied by Fe
isotope fractionation.10,14,15 Consequently, inherited or acquired
conditions leading to an impairment of Fe regulation may also
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affect the blood Fe isotopic composition, which makes this para-
meter a potential marker for Fe-related diseases.9,10,14,16
Fe absorption from the diet takes place at the luminal side
of the intestinal enterocytes.1,17 Non-heme Fe is taken up by the
cell in the Fe2+ form through the divalent metal ion transporter
1 (DMT1), while heme Fe is bound to specific heme receptors at
the cell surface.1,18 From enterocytes into the bloodstream,
Fe is exported through the membrane transporter protein
ferroportin-1, which is the only mammalian Fe exporter.19 Encoded
by SLC40A1, ferroportin is mainly expressed on the basolateral
membrane of duodenal enterocytes and liver hepatocytes, and on
the membrane of reticuloendothelial macrophages.1,19 The ferro-
portin Q248H mutation is a mutation in the ferroportin gene,
and is very common among the Bantu population (a subgroup of
Africans).20 This polymorphism is associated with an autosomal
dominant hereditary Fe overload disease, hemochromatosis type
IV.21 A possible link between the ferroportin Q248H mutation and
diabetes in South Kivu’s community has been suggested.22 South
Kivu is an Fe-rich volcanic region located in the east of the
Democratic Republic of Congo, which is mostly inhabited by Bantu
populations, where a high prevalence of diabetes has been
reported. Within this region, the ferroportin Q248H mutation
frequency approaches 14%.23
Fe overload has been incriminated in the pathogenesis
of diabetes mellitus, although this metabolic disease could
also be the underlying cause of hyperferritinemia.24–26 The
pathogenic role of Fe in the incidence of diabetes mellitus
has been demonstrated in individuals with hemochromatosis
type I and with thalassemia,25 and even in the absence of both
diseases but with evidence of high Fe status conditions.27
The main aim of this study was to evaluate the potential
eﬀect of diﬀerent endogenous conditions (such as the occurrence
of the Q248H ferroportin mutation and the high prevalence of
diabetes mellitus) within the South Kivu population studied on the
whole blood Fe isotopic signature as a case study. To this aim,
diﬀerent study groups within this population were selected based
on the expression of the ferroportin Q248H mutation and the
evidence of diabetes.
2. Experimental
2.1. Study participants
Forty-two male subjects living in Bukavu (South Kivu) were
enrolled in this study: twenty-six controls showing no ferroportin
Q248H mutation (wild-type group), twelve Q248H heterozygotes
and four homozygotes. The median age of the study population
was 53 years (IQR: 48–59 years). There was no difference in age
between the groups. None of the patients had been treated for
Fe overload by phlebotomy at the moment of blood sample
collection. As inflammatory conditions also have an influence
on several Fe-status parameters (such as serum ferritin and
hepcidin concentrations or transferrin saturation), subjects with
a serum C-reactive protein (CRP) concentration of 410 mg L1
(potentially indicative of inflammation) were excluded from the
study. Within the wild-type and the ferroportin Q248H mutation
group, ten (37%) and eight subjects (53%), respectively, were
diabetic. The presence of diabetes mellitus was proven according
to the American Diabetes Association criteria.28 The ferroportin
Q248H heterozygotes and homozygotes were considered to be the
mutation positive group for further statistical analyses. Ethical
permission was granted by the Ethical committee of the Universite´
catholique de Bukavu (No. 011/2012) and informed consent was
obtained from all the participants.
2.2. Reagents and standards
Ultrapure water (18.2 MO cm at 25 1C) was obtained from an
Element Milli-Q water purification system (Merck Millipore,
USA). For sample digestion, preparation and sample/standard
dilutions, 14 M pro-analysis purity grade HNO3 (ProLabo,
Belgium) was used after sub-boiling distillation in a PFA system.
9.8 M H2O2 TraceSELECT ultra pure (Fluka, Sigma-Aldrich,
Belgium) was used for sample digestion. Optimal grade 12 M
HCl (Fisher Chemical, UK) was used for Fe chromatographic
isolation.
All single-element standard solutions used for quantification
and isotopic analysis were purchased from Inorganic Ventures
(The Netherlands) at a concentration of 1 g L1. The Fe isotopic
reference material IRMM-014 (Institute for Reference Materials
and Measurements, Belgium) was used for external mass bias
correction.
The analytical grade AG MP-1 strong anion exchange resin
(100–200 mm dry mesh size, chloride form) and PolyPrep
polypropylene chromatographic columns were purchased from
Bio-Rad (Belgium) and used for Fe isolation from the sample
matrix.
2.3. Sample collection and treatment
Blood samples were collected in a fasting state, in a dipotassium
ethylenediaminetetraacetic acid (K2EDTA) tube for whole blood
isotopic analysis and in a serum tube for the determination of
clinical Fe parameters. The samples were stored at 20 1C before
being transported to Ghent University (Belgium) for further clinical
assays and isotopic analysis.
Acid digestion of the samples was performed in closed
Teflon Savillexs beakers with a mixture of 4 mL of HNO3
(14 M) and 1 mL of H2O2 (9.8 M). These mixtures were heated
on a hotplate set at 110 1C for 18 hours. The digests were then
evaporated to dryness at 95 1C and the obtained residues were
re-dissolved in 5 mL of 8 M HCl. The samples were passed
through a 1 mL AG MP-1 anion exchange resin packed in a
polypropylene column for the chromatographic isolation of Fe.
Briefly, after thorough cleaning and conditioning of the resin
with 8 M HCl, the sample digest was loaded into the column.
The matrix components were eluted with 3 mL of 8 M HCl,
followed by 9 mL of 5 M HCl. Then, 7 mL of 0.6 M HCl was
passed through to quantitatively elute Fe from the column.
In all of the previous steps, the solutions were doped with a
small amount (0.001%) of H2O2 to ensure an appropriate
oxidation state of Fe. The Fe fraction was collected in a pre-
cleaned Teflon Savillexs beaker and evaporated to dryness at
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95 1C. It was then re-dissolved in 1 mL of 14 M HNO3, and this
evaporation/redissolution step was repeated twice to reduce the
chlorine content to the largest extent possible. The final residue
was re-dissolved in 0.5 mL of 0.42 M HNO3 for subsequent
quantification and isotopic analysis.
Digestion and Fe isolation procedures were performed
inside a class 10 cleanroom. Teflon Savillexs beakers were
previously cleaned in 2 steps with 7 M HNO3 followed by two
steps with 6 M HCl at 110 1C and were rinsed with Milli-Q water
between the steps. All other materials used (pipette tips,
Eppendorf and centrifuge tubes) were previously cleaned using
1.4 M HNO3 and Milli-Q water.
2.4. Instrumentation and measurements
2.4.1. Clinical assays. Prior to isotopic analysis, the samples
were characterized for their Fe status and other relevant para-
meters (Table 1). The data for each individual are provided in the
ESI† (Table S1). The serum Fe concentration was determined
using a ferrozine-based colorimetric assay, whereas transfer-
rin was measured using immunoturbidimetry. Both analytes
were determined on a Cobas 8000 system (Roche, Germany).
Ferritin was measured using an electrochemiluminiscence-
based immunoassay on a Modular E analyser (Roche, Germany).
Hemoglobin A1c (HbA1c) was assayed on K2EDTA blood speci-
mens using a Menarini 8160 high-performance liquid chroma-
tography (HPLC) system (Menarini, Italy) with photometric
detection.
The ferroportin Q248H mutation (rs11568350 (G;T)) was
identified as previously reported.29 In brief, DNA was isolated
from whole blood using a Qiagen QIAamp Blood Kit. Exon 6 of
ferroportin was amplified using a set of primers, encompassing
portions of the introns that flank the exon (forward primer:
50-CAT GGC CTG TGG CTT TATT-30, reverse primer: 50-GCT
CAC ATC AAG GAA GAG GG-30). After initial denaturation at
near 94 1C for 10 min, PCR was performed for 5 cycles of
heating at 94 1C for 45 s, cooling at 56 1C for 45 s and heating at
68 1C for 45 s. This was followed by 25 cycles of heating at 94 1C
for 45 s, cooling at 52 1C for 45 s and heating at 68 1C for 45 s
with a final cycle of 15 min at 68 1C in a thermocycler (PTC-100,
MJ Research Inc, MA, USA). The 392-base pair (bp) product was
digested with PvuII enzyme (MBI Fermentas, Germany, 140 bp),
then fractioned in a 3% agarose gel with ethidium bromide and
detected.
2.4.2. Isotopic analysis. Before and after chromatographic
isolation, the total Fe concentration in the samples was deter-
mined to ensure the quantitative recovery and discard potential
on-column isotope fractionation eﬀects. An Element XR single-
collector sector field ICP-MS instrument (Thermo Scientific,
Germany) was used for this purpose. As a sample introduction
system, a quartz concentric nebulizer (200 mL min1) and a
cyclonic spray chamber were used. The samples and external
calibration standards were properly diluted with 0.42 M HNO3
and Ga was added as an internal standard, at a concentration of
10 mg L1, to correct for non-spectral interferences and instru-
ment instability. All instrument settings and data acquisition
parameters are given in the ESI† (Table S2).
Isotope ratio measurements were carried out using a
Thermo Scientific Neptune multi-collector ICP-MS instrument,
with a sample introduction system consisting of a low-flow
PFA concentric nebulizer (100 mL min1) and a quartz spray
chamber with a cyclonic and a Scott-type sub-unit. A large dry
interface pump, an X-type Ni skimmer and a jet-type Ni
sampling cone were used to improve the sensitivity. Detailed
instrument settings and data acquisition parameters are pre-
sented in Table 2.
For mass bias correction purposes, a combination of external
(a sample-standard bracketing approach) and internal (using
admixed Ni as an internal standard) correction was used. The
revised Russell’s model for calculating the mass bias factors as
described by Baxter et al. was applied oﬀ-line.30 The isotopic
composition is expressed in delta notation (d56Fe and d57Fe, %)
relative to the IRMM-014 Fe isotopic reference material, as
described elsewhere.5,31
2.5. Statistical analysis
Statistical analyses were performed using the MedCalc software
(MedCalc, Belgium). The data are expressed as median 
interquartile range (IQR) or means  standard deviation (SD)
where appropriate. The diﬀerences between patient groups
were evaluated using the chi-square test or the Student’s t-test.
Pearson or Spearman’s rank correlation coeﬃcients were used
to explore the relationships. Multiple linear regression analysis
was performed with the d56Fe ratio as a dependent variable.
Agreement with the Hardy–Weinberg equilibrium was verified
using a chi-square test. A p valueo of 0.05 was considered to be
statistically significant.
Table 1 Overview of the clinical and biological parameters according to the ferroportin Q248H mutation status. Age, body mass index, serum iron
concentration, d56Fe value, d57Fe value, serum ferritin concentration, transferrin saturation, transferrin concentration and HbA1c values were similar in the
diﬀerent groups. The values are represented as a median (with their interquartile range)
Q248H positive (n = 15) Wild type (n = 27) p-Value
Age (years) 54 (52–62) 57 (52–69) NS
BMI (kg m2) 23.4 (22.1–24.3) 22.3 (20.3–24.9) NS
Fe (mg dL1) 101 (86.9–120.4) 92.3 (76.6–107.3) NS
d56Fe (%) 2.87 (2.95 to 2.76) 2.96 (3.08 to 2.78) NS
d57Fe (%) 4.22 (4.34 to 4.05) 4.34 (4.56 to 4.10) NS
Ferritin (mg L1) 211 (142–476) 228 (115–540) NS
Transferrin (g L1) 2.5 (2.4–2.6) 2.4 (2.1–2.6) NS
Transferrin saturation (%) 33.5 (28.5–41.3) 31.0 (27.1–35.4) NS
Hb A1c (mmol mol1) 42.0 (34.2–52.5) 35.0 (31.0–51.0) NS
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3. Results and discussion
3.1. Correlation of Fe status parameters with whole blood Fe
isotopic composition
The Fe isotopic pattern in whole blood is determined both
by the Fe intestinal absorption eﬃciency and fractionation
during partitioning of Fe between blood and the Fe-storage
organs.6,7,9,15 In assumed healthy individuals, the preferential
uptake of light isotopes by duodenal enterocytes, as well as the
preferential accumulation of heavier isotopes in the storage
organs, contribute to a lighter isotopic signature in blood than
that of the average diet.32 However, this normal trend is altered
when dysfunction of the Fe regulation mechanisms is present.
The serum ferritin concentration is the current parameter of
choice when evaluating an individual’s Fe status. However,
ferritin is an acute-phase reactant and its concentration in
serum increases with the prevalence of infection or inflammation.
For this reason, to interpret serum ferritin levels, other Fe status
parameters irresponsive to inflammatory states (such as the
soluble transferrin receptor concentration) are usually monitored
alongside, as well as other acute-phase response proteins (such as
C-reactive protein or a1-acid-glycoprotein).
33
A significant inverse correlation between the serum ferritin
concentration and the d56Fe value exists according to the
Spearman’s rank correlation coeﬃcient (r = 0.559, p = 0.0001)
taking into account the whole population of this study, as shown
in Fig. 1. This is in good agreement with the previous findings.6–11
A low serum ferritin concentration corresponds to a low Fe status.
As responsive mechanisms, both upregulation of Fe absorption
and Fe release from the stores would lead to heavier d56Fe values
in blood. In contrast, a high Fe status (reflected in a high serum
ferritin concentration) would trigger a downregulation in Fe
absorption and Fe sequestration in a non-redox active metallo-
protein form (ferritin) within the storage organs, maintaining a
lighter Fe isotopic composition in the circulating blood. In the
same way, an inverse relation between the serum ferritin concen-
tration and intestinal Fe absorption has been demonstrated.12
The correlation between the serum ferritin concentration
and d56Fe values was further confirmed by multiple regression
analysis (Table 3).
In a previous study with a European population, it was
found that, although the correlation is not as marked as in
the case of ferritin, both transferrin and transferrin saturation
exhibited a positive and negative relationship with d56Fe values,
respectively.6 However, in this African population, neither the
transferrin concentration, nor the transferrin saturation para-
meters showed any significant correlation with the Fe isotopic
composition in blood. All individuals of the South Kivu popula-
tion in the current study present transferrin concentrations in
serum lower than 3 g L1, while in the European population
most individuals showed transferrin concentrations between
3 and 5 g L1. Moreover, most of these African individuals have
a transferrin saturation above 25% and a median d56Fe leading
to a high Fe status value (d56Fe = 2.94%). The d56Fe ratio in
the whole blood from the reference population in this study
ranged from 3.09% to 2.41%. Thus, a possible explanation
for this diﬀerent behavior between the populations may be the
fact that South Kivu is an Fe-rich volcanic region, which may
have a significant influence on the amount of bioavailable Fe
in the ecosystem. As a matter of fact, sub-Saharan African
populations have been previously characterized to present a
predisposition to Fe overloading reaching 10% of the population
and believed to arise in part from an excessive dietary intake of Fe
together with a genetic factor.34
Finally, also no significant correlation between serum Fe
concentration and d56Fe was found. The whole blood Fe
isotopic composition of the South Kivu population under study
leads to lower d56Fe values than those of the European popula-
tions reported in previous studies. A comparative boxplot
presentation based on the data for several populations found
in the literature and the one of the present study is displayed in
Fig. 2. All data selected for comparison are derived from Fe
isotopic studies in whole blood and all have been expressed
Table 2 Instrument settings and data acquisition parameters for Fe
isotopic analysis using a Thermo Scientific Neptune MC-ICP-MS
Instrument settings
RF power (W) 1250
Guard electrode Connected
Sampler cone Ni; jet-type; 1.1 mm aperture
diameter
Skimmer cone Ni; X-type; 0.8 mm aperture diameter
A Large dry interface pump
(m3 h1)
130
Lens settings Optimized for a maximum
analyte signal intensity
Plasma gas flow rate (L min1) 15
Auxiliary gas flow rate (L min1) 0.75
Nebulizer gas flow rate (L min1) 1.000
Sample uptake rate (mL min1) 100
Resolution Medium (4000)
Data acquisition parameters
Acquisition mode Static; multi-collection
Number of blocks 9
Number of cycles/blocks 5
Integration time (s) 4.194
Cup configuration L4: 54Fe, L2: 56Fe, L1: 57Fe, C:
(58Fe + 58Ni), H1: 60Ni, H3: 62Ni
Fig. 1 Whole blood d56Fe value as a function of serum ferritin concentration
(d56Fe (%) = 0.0003 ferritin (mg L1) 2.8) (r = 0.559, p o 0.0001).
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against the same Fe isotopic standard (IRMM-014). From each
study, only male and postmenopausal female subjects have
been taken into account.
3.2. Influence of the ferroportin Q248H mutation on the Fe
isotopic signature
Studies in patients with hemochromatosis type I have demon-
strated that the blood Fe isotopic signature leads to heavier
values due to an elevated Fe uptake. When these patients are
treated with phlebotomy, the blood Fe isotopic composition
also becomes heavier4,29 due to the increased presence in the
blood of Fe originating from the stores.7
Along with environmental causes, the abnormal Fe loading
of the African population implies a genetic susceptibility. The
pattern of Fe distribution within the body of these individuals
diﬀers from that caused by hereditary hemochromatosis.
In addition to Fe accumulation in the hepatocytes, the Kupﬀer
cells also act as the main deposition sites in the liver and a
more general accumulation of Fe throughout diﬀerent organs
was recorded.35
The ferroportin Q248H mutation is a common polymorphism
among African natives, aﬀecting more than 10% of the
population.23 It has been reported to be resistant to the
physiological concentration of hepcidin,36 resulting in elevated
duodenal Fe absorption, leading to increased Fe stores24,36 and
a protective eﬀect against anemia.29 Despite these arguments,
the ferroportin Q248H mutation did not aﬀect the iron isotopic
composition (Table 1). In this study no diﬀerence of serum
ferritin concentrations between the diﬀerent groups according
to the ferroportin Q248H mutation was observed, suggesting
that the subjects included did not yet develop the disease or
showed an incomplete penetrance of the mutation. Also none
of them had been treated for Fe overload by phlebotomy, which
could increase the presence of Fe originating from the stores.
Furthermore, it has been demonstrated that although the muta-
tion is associated with an increase in Fe absorption, the clinical
expression is associated with other factors such as inflammation29
or alcohol consumption.37 In this study, subjects with a serum
C-reactive protein (CRP) concentration of410 mg L1 (potentially
indicative of inflammation) were excluded.
3.3. Relationship between the whole blood Fe isotopic
composition and diabetes
Previously, a link between increased Fe stores and the prevalence
of diabetes has been established.25,26 While the mechanism of
this interaction is not completely understood, it is speculated that
Fe accumulation in the liver and pancreas impedes proper insulin
secretion and may stimulate the development of insulin
resistance.23
The whole blood Fe isotopic composition was explored in
diabetic and non-diabetic patients of the South Kivu population.
As shown in Fig. 3, in comparison to non-diabetic patients,
subjects with diabetes, present a heavier whole blood Fe
isotopic composition, which corresponds to an upregulated Fe
metabolism.7 Insulin has been reported to stimulate hepcidin
secretion via STAT3.38 Wang et al. have demonstrated that
rats with diabetes present a significant reduction in hepcidin
expression in the liver, mediated by STAT3, causing abnormally
increased expression of ferroportin in the intestine, leading to
Table 3 Multiple regression analysis with the d56Fe ratio as a dependent variable
b (SE) p-Value
d56Fe r2 = 0.35, p o 0.001 Diabetes mellitus 0.302 (0.078) NS
BMI 0.407 (0.008) o0.05
Ferroportin Q248H mutation 0.203 (0.053) NS
HbA1c 0.134 (0.002) NS
Ferritin concentration 0.406 (0.0001) o0.05
Multiple regression analysis with the d56Fe ratio as a dependent variable. Serum ferritin concentration and BMI are correlated to the iron isotopic
composition. The presence of diabetes, HbA1c and the ferroportin Q248Hmutation did not show any correlation with the whole blood d56Fe value.
Fig. 2 Comparative boxplot of the whole blood Fe isotopic composition
between diﬀerent populations. Along with the population of this study
(South Kivu), the data included were extracted from Van Heghe et al.
(Belgian population),6 Walczyk and von Blanckenburg (Swiss population),32
Albare`de et al. (French population)8 and Jaouen et al. (Yakut population).14
Fig. 3 Box plot of the whole blood Fe isotopic composition from diabetic
and non-diabetic individuals.
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high serum Fe concentrations.39 Furthermore, it has been
demonstrated that the release of insulin by pancreatic beta
cells is associated with a concomitant production of hepcidin.40
Subjects with type 2 diabetes have been reported to exhibit a
lower concentration of circulating hepcidin in comparison to
nondiabetic patients in a population matched for age, gender
and BMI.41,42
In the same way, a relation between the whole blood Fe
isotopic composition and the glycated hemoglobin A1c (HbA1c)
has also been observed according to the Spearman’s rank
correlation coeﬃcient (r = 0.26, p 4 0.05), as shown in Fig. 4.
HbA1c is a form of hemoglobin determined for diagnosis and
follow-up for diabetes, as it reflects an average measure of the
plasma glucose concentration. However, after correction for
multiple testing, these associations were no longer evident
(Table 3). In a recent study evaluating the Fe isotopic composi-
tion of subjects presenting hemochromatosis type I, diabetic
subjects seemed to have a heavier Fe isotopic composition than
non-diabetic subjects, but the number of diabetic subjects
(n = 3) was too low for proper statistical evaluation.10 Despite
the lack of significance in the multiple testing model, these
results highlight the influence of Fe metabolism in the course
of diabetes mellitus.
3.4. Body mass index influence on Fe status
Finally, a significant inverse relationship of the body mass
index (BMI) of the population under study with d56Fe values
was found according to the Spearman’s rank correlation coeﬃ-
cient (r = 0.462 p o 0.005), shown in Fig. 5, and multiple
regression analysis (Table 3).
Among the population under study, 2 individuals presented
a BMI below 18.5 kg m2 (underweight/malnutrition), 30
individuals had a BMI ranging from 18.5 to 24.9 kg m2
(normal weight), 8 individuals displayed values in the region
between 25.0 and 29.9 kg m2 (overweight) and only 1 subject
had a BMI corresponding to an obesity status (equal to or above
30 kg m2).
Although subjects with clear signs of inflammation (CRP
410 mg L1) were excluded from this study, CRP values
ranging from 1 to 5 mg L1 (a possible indication of low-
grade inflammation) were determined for several overweight
individuals and the subject with obesity. Normal weight indi-
viduals had a CRP value below 1 mg L1.
Previous research has shown that there is an inverse rela-
tionship between BMI and Fe intestinal absorption.43 Due to
subclinical inflammation associated with obesity, which leads
to an increase of hepcidin secretion,44 obese subjects display
a lower Fe absorption compared to overweight and normal
weight subjects.45 Furthermore, a significant correlation between
serum hepcidin concentration and BMI has also been reported.44
This downregulation in the Fe absorption eﬃciency associated
with an increased BMI would explain the inverse correlation of the
d56Fe values with BMI.
Although obesity is known as a risk factor for type 2
diabetes, the hepcidin expressions during type 2 diabetes or
obesity have been reported to be diﬀerent. While overweight
and obese subjects exhibit high concentrations of serum
hepcidin, type 2 diabetes is associated with insuﬃcient hepcidin
Fig. 4 Whole blood d56Fe value as a function of HbA1c (d56Fe (%) =
0.003 HbA1c (mmol mol1) 3.03) (r = 0.26, p 4 0.05).
Fig. 5 Whole blood d56Fe value as a function of BMI (d56Fe (%) =0.0443
BMI (kg m2) 3.26) (r = 0.462, p o 0.005).
Fig. 6 Schematic of the potential mechanisms underlying the interplay
between type 2 diabetes, BMI, ferroportin Q248Hmutation and Fe isotopic
composition.
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production. A schematic illustrating the mechanisms at play is
shown in Fig. 6.
It is worth mentioning here that only 15% of the diabetic
patients participating in this study were overweight, while the
rest were normal or underweight. Previously, it has been
observed in South Kivu that only 18% of subjects with diabetes
were obese and that the disease was associated with a low
percentage of insulin resistance.46 Furthermore, a link between
diabetes and iron stores (expressed by hyperferritinemia) was
observed in the same region.22 Therefore, it is assumed that
Fe overload may be regarded as a potential driving cause for
diabetes.
4. Conclusions
Whole blood Fe isotopic analysis has been used to study the
influence of several endemic characteristics of an African
population of the South Kivu region on an individual’s Fe
status. The community of this Fe-rich volcanic region in the
Democratic Republic of Congo shows a 14% ferroportin Q248H
mutation incidence. This polymorphism is associated with
Fe overload hereditary hemochromatosis type IV. Among the
population under study, wild-type, heterozygotes and homozygotes
were compared. While a clear inverse correlation between the
serum ferritin concentration and the d56Fe value in whole blood
was obtained, no significant diﬀerences between subjects presenting
the ferroportin mutation and the wild-type group were observed.
In all cases, the d56Fe values ranged from 3.32% to 2.41%.
This range is lower than that of European populations, which is
hypothetically attributed to the high concentration of Fe in their
living environment and the corresponding higher uptake. The
absence of a diﬀerence in the whole blood Fe isotopic composi-
tion between subjects with the ferroportin mutation and the
wild-type group, linked to the fact that none of the individuals of
the cohorts presenting the mutation showed comparable serum
ferritin concentrations to those of a hemochromatosis spectrum,
indicates that none of the subjects had yet developed symptoms
of the disease.
A link between the ferroportin Q248H mutation and diabetes
has been previously suggested. Clinical evidence for a link
between increased Fe stores and the development of diabetes
mellitus exists. In the South Kivu population, the whole blood
d56Fe value was significantly higher in diabetic patients compared
to non-diabetic patients. Finally a significant correlation of the Fe
isotopic composition in whole blood with the BMI was also found,
evidencing the eﬀects of low-grade inflammation accompanying
overweight status and obesity on the Fe status.
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